ADHD Drugs Under Scrutiny by RFK Jr.’s Make America Healthy Again (MAHA) Commission

Everydayhealth.com, March 17, 2025: President Trump’s executive order will create a MAHA Commission to examine the use of ADHD and psychiatric drugs for children. This news article focuses on whether access to ADHD drugs will harm children. NCHR reassures parents that access is unlikely to be harmed. We view the Commission as a good idea, but those views were not included in the article.

Read More »

The FDA’s misguided thinking on antibiotics

STAT, February 10, 2025: Why are so many people dying from infections? In this op-ed, Diana Zuckerman and John Powers discuss that the main problem isn’t antimicrobial resistance; the problem is the way antibiotics are studied and approved. Research shows we can save lives with better studies and FDA approval standards that focus on patients and not bugs.

Read More »

Pfizer hires FDA drug regulator Cavazzoni, sparking revolving door debate

Politico, February 24, 2025: FDA Director of Drug Center (CDER), Cavazzoni, returns to Pfizer, where she worked before going to the FDA. NCHR and other experts say this revolving door undermines trust in the FDA and highlights concerns about the cozy relationship between the FDA and industry that can weaken standards of safety and effectiveness.

Read More »

The Deadly Secrets Behind “Breakthrough” Alzheimer’s Drugs

The Lever, January 28, 2025: We are working with a consortium of experts to expose problems with FDA approvals. Our first article published in The Lever focuses on the clear risks and questionable benefits of drugs for early cognitive impairment caused by Alzheimer’s and how conflicts of interest resulted in approval.

Read More »